98%
921
2 minutes
20
Smith-Magenis syndrome (SMS) is a complex genetic disorder characterized by developmental delay and a typical behavioral phenotype. Interstitial 17p11.2 deletions, which include the RAI1 gene are detected in >90% of patients, while single nucleotide variants (SNVs) are detected in the rest. The gene is encoded from exons 3 onwards, while exons 1-2 are noncoding. It is unclear whether genetic variants preceding exon 3 cause SMS. We evaluated a 15-month-old infant for developmental delay and infantile spasms who was found to carry a deletion encompassing exons 1-2 of . To determine whether the deletion of the noncoding exons 1-2 of the gene is associated with SMS and to elucidate the underlying mechanism of this association. A singleton exome-based gene panel was performed, followed by chromosomal-microarray (CMA) to confirm the results. Real time quantitative PCR (RT-qPCR) analysis was conducted to evaluate mRNA expression. CMA confirmed a de novo 737.8 kbp deletion on 17p11.2, which includes exons 1-2 of but spares exons 3 onwards. RT-qPCR analysis on RNA extracted from the patient, father and three unrelated controls revealed that the patient has haploinsufficiency. We show that deletion of the noncoding exons 1-2, which spares the gene's coding region, causes haploinsufficiency by eliminating regulatory elements, including the gene promoter, thus causing SMS and expanding the mutational spectrum of SMS.
Download full-text PDF |
Source |
---|
Neurology
October 2025
Department of Neurology, Leiden University Medical Center, the Netherlands.
Background And Objectives: Slow and highly variable disease progression in Becker muscular dystrophy (BMD) stresses the need to develop sensitive outcome measures for clinical trials. We evaluated responsiveness of different outcome measures in adult patients with BMD over 3 years and explored if the sensitivity of outcome measures can be increased by selecting on phenotype or genotype.
Methods: Genetically confirmed patients with BMD were recruited via the Dutch Dystrophinopathy Database.
Mol Cytogenet
August 2025
Department of Medical Genetics and Genomics, School of Medicine, Sapporo Medical University, 1 West 17, Chuo-ku, Sapporo, 060-8556, Japan.
Unlabelled: Peutz–Jeghers syndrome is an autosomal dominant disease characterized by intestinal polyposis, mucocutaneous pigmentation, and an increased risk of various types of cancer. Germline mutations in (), which encodes serine/threonine kinase 11, have been identified as the major cause of Peutz–Jeghers syndrome. Here, we detected a rare variant of undetermined significance in intron 2 of using multi-gene panel analysis in a girl with clinically suspected Peutz–Jeghers syndrome.
View Article and Find Full Text PDFBlood
August 2025
Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, France.
Venous thromboembolism (VTE) is a frequent (annual incidence of 1-2 per 1,000) and potentially life-threatening (case-fatality rate up to 10%) disease. VTE is associated with serious short-term and long-term complications, including a recurrence rate approaching 20% within five years. Anticoagulant therapy, the mainstay of VTE treatment, drastically reduces the risk of early VTE recurrence, but it exposes patients to a substantial risk of bleeding.
View Article and Find Full Text PDFBiochem Genet
August 2025
Department of Animal Production, College of Agriculture, Al-Qasim Green University, Al-Qasim, Babil, Iraq.
LIM homeobox transcription factor 4 (LHX4) is one of the genes involved in sheep reproduction. Consequently, this study investigated whether the LHX4 gene affects the litter size of ewes. Genomic DNA extraction was performed on 123 ewes with singleton lambs and 109 ewes with twins.
View Article and Find Full Text PDFClin Cancer Res
July 2025
Repare Therapeutics, Cambridge, MA, United States.
Purpose: The development of DNA damage response (DDR)-directed therapies is a major area of clinical investigation, yet to date Poly (ADP-ribose) polymerase inhibitors (PARPi) remain the only approved therapy in this space. Major challenges to DDR-targeted therapies in the post-PARPi era are the context dependency of DDR alterations and the presence of pre-existing resistance in this heavily pre-treated population. Blood samples from patients with tumors harboring defects in DDR genes were evaluated the feasibility of liquid biopsy platform for detecting complex genomic events such as BRCA1/2 reversions, HRD signatures, PV allele status, and differentially methylated regions for accurate quantitation of TF.
View Article and Find Full Text PDF